|
Jul 31
|
Insmed’s Pipeline Growth With Brensocatib Approval And Phase 3 Trials
|
|
Jul 31
|
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
|
|
Jul 31
|
Strong Drug Development Momentum Lifted Insmed Incorporated (INSM) in Q2
|
|
Jul 30
|
Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.
|
|
Jul 28
|
Synthetic rescue: Insmed explores a new frontier in genetic therapeutics
|
|
Jul 24
|
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
|
|
Jul 24
|
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
|
|
Jul 17
|
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
|
|
Jul 14
|
Jim Cramer Calls Insmed “Very Speculative”
|
|
Jul 14
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 30
|
United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says
|
|
Jun 18
|
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
|
|
Jun 17
|
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107
|
|
Jun 17
|
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating
|
|
Apr 8
|
Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires?
|
|
Feb 24
|
International Markets and Insmed (INSM): A Deep Dive for Investors
|
|
Feb 24
|
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
|
|
Feb 21
|
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
|
|
Feb 21
|
Insmed Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 21
|
Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
|